VIGONVITA-B (02630) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express03-19 06:23

Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B, 02630) has announced that its board of directors will convene on 31 March 2026. The agenda includes:

• Reviewing and approving the Group’s audited financial results for the year ended 31 December 2025.

• Deliberating on the declaration of a final dividend, if any.

• Addressing other routine corporate matters.

Board composition at the date of the notice comprises six members: Executive Directors Dr. Tian Guanghui (also Chairman, CEO and General Manager) and Dr. Hu Tianwen; Non-executive Director Mr. Liu Haoxuan; and Independent Non-executive Directors Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.

The company will publish its FY2025 annual results following the board’s deliberations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130554739?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130554739","market":"us","top_or_hot":-1,"title":"VIGONVITA-B (02630) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B, 02630) has announced that its board of directors will convene on 31 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s audited financial results for the year ended 31 December 2025.</p>\n<p>• Deliberating on the declaration of a final dividend, if any.</p>\n<p>• Addressing other routine corporate matters.</p>\n<p>Board composition at the date of the notice comprises six members: Executive Directors Dr. Tian Guanghui (also Chairman, CEO and General Manager) and Dr. Hu Tianwen; Non-executive Director Mr. Liu Haoxuan; and Independent Non-executive Directors Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.</p>\n<p>The company will publish its FY2025 annual results following the board’s deliberations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VIGONVITA-B (02630) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVIGONVITA-B (02630) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-19 06:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B, 02630) has announced that its board of directors will convene on 31 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s audited financial results for the year ended 31 December 2025.</p>\n<p>• Deliberating on the declaration of a final dividend, if any.</p>\n<p>• Addressing other routine corporate matters.</p>\n<p>Board composition at the date of the notice comprises six members: Executive Directors Dr. Tian Guanghui (also Chairman, CEO and General Manager) and Dr. Hu Tianwen; Non-executive Director Mr. Liu Haoxuan; and Independent Non-executive Directors Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.</p>\n<p>The company will publish its FY2025 annual results following the board’s deliberations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1130554739","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130554739","pubTimestamp":1773872594,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B, 02630) has announced that its board of directors will convene on 31 March 2026. The agenda includes: • Reviewing and approving the Group’s audited...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"VIGONVITA-B(02630)定于2026年3月31日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B, 02630) has announced that its board of directors will convene on 31 March 2026. The agenda includes:\n• Reviewing and approving the Group’s audited financial results for the year ended 31 December 2025.\n• Deliberating on the declaration of a final dividend, if any.\n• Addressing other routine corporate matters.\nBoard composition at the date of the notice comprises six members: Executive Directors Dr. Tian Guanghui (also Chairman, CEO and General Manager) and Dr. Hu Tianwen; Non-executive Director Mr. Liu Haoxuan; and Independent Non-executive Directors Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.\nThe company will publish its FY2025 annual results following the board’s deliberations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130554739","isCrawlerRequest":true}